We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA’s PRAC Against Jazz’s Defitelio as Rare Liver Disease Preventive
EMA’s PRAC Against Jazz’s Defitelio as Rare Liver Disease Preventive
The European Medicines Agency’s (EMA) safety committee has warned that Jazz Pharmaceuticals’ Defitelio (defibrotide) should not be used for preventing veno-occlusive disease (VOD) — a rare condition in which veins in the liver become clogged and stop the liver from functioning properly.